Table of Contents
Advances in Hepatology
Volume 2015, Article ID 596829, 11 pages
http://dx.doi.org/10.1155/2015/596829
Review Article

Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up

1Paris 6 University, Nephrology Department, Pitie-Salpetriere University Hospital, Paris 75013, France
2Liver Unit, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
3New Zealand Liver Transplant Unit, University of Auckland, Auckland 1010, New Zealand
4Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
5Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
6Department of Internal Medicine and Medical Specialities (Di.Bi.M.I.S.), University of Palermo, 90133 Palermo, Italy
7NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songklanagarind Hospital, Hat Yai, Songkhla 90110, Thailand
8Paris 5 University, Inserm U-1016, Hepatology Department, Cochin University Hospital, Paris 75005, France

Received 1 September 2014; Accepted 4 February 2015

Academic Editor: Jose J. Marin

Copyright © 2015 Gilbert Deray et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. McMahon, “Epidemiology and natural history of hepatitis B,” Seminars in Liver Disease, vol. 25, supplement 1, pp. 3–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. K. N. Lai, P. K. T. Li, S. F. Lui et al., “Membranous nephropathy related to hepatitis B virus in adults,” The New England Journal of Medicine, vol. 324, no. 21, pp. 1457–1463, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Deterding, N. Lampe, J. Reijnders et al., “Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European VIRGIL cohort,” in Proceedings of the 46th Annual Meeting of the European Association for the Study of the Liver (EASL '11), Berlin, Germany, March-April 2011.
  5. N. B. Ha, R. T. Garcia, H. N. Trinh et al., “Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil,” Hepatology, vol. 50, no. 3, pp. 727–734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. N. Lai, P. K. T. Li, S. F. Lui et al., “Membranous nephropathy related to hepatitis B virus in adults,” The New England Journal of Medicine, vol. 324, no. 21, pp. 1457–1463, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Deterding, N. Lampe, J. Reijnders et al., “Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European VIRGIL cohort,” in Proceedings of the 46th Annual Meeting of the European Association for the Study of the Liver (EASL '11), Berlin, Germany, March 2011.
  8. N. B. Ha, N. B. Ha, R. T. Garcia et al., “Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil,” Hepatology, vol. 50, no. 3, pp. 727–734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Fabrizi, P. Messa, and P. Martin, “Hepatitis B virus infection and the dialysis patient,” Seminars in Dialysis, vol. 21, no. 5, pp. 440–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. O. Ozdamar, S. Gucer, and K. Tinaztepe, “Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children,” Pediatric Nephrology, vol. 18, no. 1, pp. 23–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Bhimma and H. M. Coovadia, “Hepatitis B virus-associated nephropathy,” American Journal of Nephrology, vol. 24, no. 2, pp. 198–211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Yi, Y. W. Jie, and Z. Nan, “The efficacy of anti-viral therapy on hepatitis b virus-associated glomerulonephritis: a systematic review and meta-analysis,” Annals of Hepatology, vol. 10, no. 2, pp. 165–173, 2011. View at Google Scholar · View at Scopus
  13. E. C. Chacko, S. K. Surrun, T. P. M. Sani, and J. M. Pappachan, “Chronic viral hepatitis and chronic kidney disease,” Postgraduate Medical Journal, vol. 86, no. 1018, pp. 486–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Ren, L. Wang, Z. Chen et al., “Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy,” Journal of Medical Virology, vol. 78, no. 5, pp. 551–560, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. L. Deng, X. W. Song, H. J. Liang, C. Feng, Y. J. Sheng, and M. Y. Wang, “Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells,” World Journal of Gastroenterology, vol. 12, no. 11, pp. 1752–1756, 2006. View at Google Scholar · View at Scopus
  16. T. J. Liang, “Hepatitis B: the virus and disease,” Hepatology, vol. 49, supplement 5, pp. S13–S21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Nagy, G. Bajtai, H. Brasch et al., “The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies,” Clinical Nephrology, vol. 12, no. 3, pp. 109–116, 1979. View at Google Scholar · View at Scopus
  18. R. Bhimma, H. M. Coovadia, and M. Adhikari, “Hepatitis B virus-associated nephropathy in black South African children,” Pediatric Nephrology, vol. 12, no. 6, pp. 479–484, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Guillevin, A. Mahr, P. Callard et al., “Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients,” Medicine, vol. 84, no. 5, pp. 313–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Bhimma, M. G. Hammond, H. M. Coovadia, M. Adhikari, and C. A. Connolly, “HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy,” Kidney International, vol. 61, no. 4, pp. 1510–1515, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Cai, X. Fan, L. Mou et al., “Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1561–1566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-J. Lee, M.-Y. Lin, Y.-H. Yang, S.-N. Lu, H.-C. Chen, and S.-J. Hwang, “Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study,” The American Journal of Kidney Diseases, vol. 56, no. 1, pp. 23–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Izzedine, V. Launay-Vacher, and G. Deray, “Antiviral drug-induced nephrotoxicity,” The American Journal of Kidney Diseases, vol. 45, no. 5, pp. 804–817, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Izzedine, V. Launay-Vacher, C. Isnard-Bagnis, and G. Deray, “Antiviral drug-induced kidney and electrolytes disorders,” Minerva Urologica e Nefrologica, vol. 55, no. 3, pp. 157–172, 2003. View at Google Scholar · View at Scopus
  25. R. J. Fontana, H.-W. L. Hann, R. P. Perrillo et al., “Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy,” Gastroenterology, vol. 123, no. 3, pp. 719–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Izzedine, J. S. Hulot, V. Launay-Vacher et al., “Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies,” Kidney International, vol. 66, no. 3, pp. 1153–1158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-F. Huang, W.-L. Chuang, C.-Y. Dai et al., “Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?” Journal of Internal Medicine, vol. 260, no. 3, pp. 255–262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. B. Ha, N. B. Ha, R. T. Garcia et al., “Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil,” Hepatology, vol. 50, no. 3, pp. 727–734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Capeillère-Blandin, V. Gausson, A. T. Nguyen, B. Descamps-Latscha, T. Drüeke, and V. Witko-Sarsat, “Respective role of uraemic toxins and myeloperoxidase in the uraemic state,” Nephrology Dialysis Transplantation, vol. 21, no. 6, pp. 1555–1563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Descamps-Latscha, T. Drüeke, and V. Witko-Sarsat, “Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy,” Seminars in Dialysis, vol. 14, no. 3, pp. 193–199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Witko-Sarsat, P. Rieu, B. Descamps-Latscha, P. Lesavre, and L. Halbwachs-Mecarelli, “Neutrophils: molecules, functions and pathophysiological aspects,” Laboratory Investigation, vol. 80, no. 5, pp. 617–654, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Wong, S. Mak, and A. K. Wong, “Management of chronic hepatitis B infection in patients with end-stage renal disease and dialysis,” Hepatitis B Annual, vol. 3, Article ID 76e105, 2006. View at Google Scholar
  33. W. T. London, J. S. Drew, E. D. Lustbader, B. G. Werner, and B. S. Blumberg, “Host responses to hepatitis B infection in patients in a chronic hemodialysis unit,” Kidney International, vol. 12, no. 1, pp. 51–58, 1977. View at Publisher · View at Google Scholar · View at Scopus
  34. P.-N. Wong, T.-T. Fung, A. N. H. Chan et al., “Unusual case of hepatitic cholestasis resembling fibrosing cholestatic hepatitis in a dialysis patient with chronic hepatitis B infection,” Journal of Gastroenterology and Hepatology, vol. 21, no. 10, pp. 1635–1637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1–S266, 2002. View at Google Scholar
  36. A. S. Levey, K.-U. Eckardt, Y. Tsukamoto et al., “Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO),” Kidney International, vol. 67, no. 6, pp. 2089–2100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Molino, F. Fabbian, M. Cozzolino, and C. Longhini, “The management of viral hepatitis in CKD patients: an unresolved problem,” International Journal of Artificial Organs, vol. 31, no. 8, pp. 683–696, 2008. View at Google Scholar · View at Scopus
  38. F. Fabrizi, P. Messa, and P. Martin, “Hepatitis B virus infection and the dialysis patient,” Seminars in Dialysis, vol. 21, no. 5, pp. 440–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Hoofnagle, “Reactivation of hepatitis B,” Hepatology, vol. 49, supplement 5, pp. S156–S165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. López-Alcorocho, G. Barril, N. Ortiz-Movilla et al., “Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients,” Journal of Medical Virology, vol. 63, no. 2, pp. 103–107, 2001. View at Publisher · View at Google Scholar
  41. P. Marcellin, E. J. Heathcote, T. Berg et al., “Effects of tenofovir disoproxil fumarate on renal function in chronic HBV patients in three global randomized studies,” in Annual Meeting of the European Association for the Study of the Liver, 2011, Poster. View at Publisher · View at Google Scholar
  42. R. G. Gish, M. D. Clark, S. D. Kane, R. E. Shaw, M. F. Mangahas, and S. Baqai, “Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B,” Clinical Gastroenterology and Hepatology, vol. 10, no. 8, pp. 941–946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Amet, J. P. Bronowicki, D. Thabut et al., “HARPE study: prevalence of renal abnormalities in chronic HBV infection,” in Proceedings of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '12), vol. 56, pp. 191A–1144A, Boston, Mass, USA, November 2012.
  44. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 800–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Marcellin, T.-T. Chang, S. G. Lim et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 808–816, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Deterding, N. Lampe, J. Reijnders et al., “Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European VIRGIL cohort,” in Proceedings of the Annual Meeting of the European Association for the Study of the Liver, 2011.
  47. M. Tanaka, F. Suzuki, Y. Seko et al., “Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B,” Journal of Gastroenterology, vol. 49, no. 3, pp. 470–480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. R. D. Cooper, N. Wiebe, N. Smith, P. Keiser, S. Naicker, and M. Tonelli, “Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients,” Clinical Infectious Diseases, vol. 51, pp. 496–505, 2010. View at Publisher · View at Google Scholar
  49. R. Scherzer, M. Estrella, Y. Li et al., “Association of tenofovir exposure with kidney disease risk in HIV infection,” AIDS, vol. 26, no. 7, pp. 867–875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. O. Monteagudo-Chu, M. H. Chang, H. B. Fung, and N. Bräu, “Renal toxicity of long-term therapy with tenofovir in HIV-infected patients,” Journal of Pharmacy Practice, vol. 25, no. 5, pp. 552–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Marcellin, E. J. Heathcote, M. Buti et al., “Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2442–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. E. J. Heathcote, P. Marcellin, M. Buti et al., “Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B,” Gastroenterology, vol. 140, no. 1, pp. 132–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Marcellin, E. Gane, M. Buti et al., “Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study,” The Lancet, vol. 381, no. 9865, pp. 468–475, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Mallet, P. Sogni, A. Vallet-Pichart et al., Renal Impairment under Nucleos(t)ide Analogs in A Monocentric Cohort of Patients with Chronic HBV Monoinfection: The BeSafe Study, abstract 1444, American Association for the Study of Liver Disease (AASLD), 2011.
  55. D. M. Gracey, P. Snelling, P. McKenzie, and S. I. Strasser, “Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection,” Antiviral Therapy, vol. 18, no. 7, pp. 945–948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. S. T. Law, K. K. Li, and Y. Y. Ho, “Acquired fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient,” The American Journal of Therapeutics, vol. 20, pp. e713–e716, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. A. A. M. Morris, S. V. Baudouin, and M. H. Snow, “Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors,” AIDS, vol. 15, no. 1, pp. 140–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. C. M. Lange, J. Bojunga, W. P. Hofmann et al., “Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function,” Hepatology, vol. 50, no. 6, pp. 2001–2006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Li, C. Zhong, S. Yang et al., “Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 32, no. 6, pp. 826–829, 2012. View at Google Scholar · View at Scopus
  60. Y.-F. Liaw, E. Gane, N. Leung et al., “2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B,” Gastroenterology, vol. 136, no. 2, pp. 486–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Wang, S. Thongsawat, E. J. Gane et al., “Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B,” Journal of Viral Hepatitis, vol. 20, no. 4, pp. e37–e46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Piratvisuth, P. Komolmit, T. Tanwandee et al., “52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B,” PLoS ONE, vol. 8, no. 2, Article ID e54279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. G. R. Matzke, G. R. Aronoff, A. J. Atkinson et al., “Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: improving Global Outcomes (KDIGO),” Kidney International, vol. 80, no. 11, pp. 1122–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B virus infection,” Journal of Hepatology, vol. 57, no. 1, pp. 167–185, 2012. View at Publisher · View at Google Scholar
  65. A. J. Atkinson Jr. and S.-M. Huang, “Nephropharmacology: drugs and the kidney,” Clinical Pharmacology & Therapeutics, vol. 86, no. 5, pp. 453–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. L. A. Stevens and A. S. Levey, “Use of the MDRD study equation to estimate kidney function for drug dosing,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 465–467, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. SiteGPR, “The reference source of information for the safe use of drugs in patients with renal disease,” http://www.sitegpr.com/.